(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of -2.78% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.5%.
Castle Biosciences's revenue in 2025 is $332,069,000.On average, 1 Wall Street analysts forecast CSTL's revenue for 2025 to be $8,303,023,400, with the lowest CSTL revenue forecast at $8,303,023,400, and the highest CSTL revenue forecast at $8,303,023,400. On average, 1 Wall Street analysts forecast CSTL's revenue for 2026 to be $8,682,831,332, with the lowest CSTL revenue forecast at $8,682,831,332, and the highest CSTL revenue forecast at $8,682,831,332.
In 2027, CSTL is forecast to generate $9,863,885,726 in revenue, with the lowest revenue forecast at $9,863,885,726 and the highest revenue forecast at $9,863,885,726.